产品中心 / 产品类型 / 重组蛋白 / 细胞因子 & 细胞因子受体

活性验证

Recombinant Mouse VEGF-D/FIGF Protein (RP01778)

Recombinant Mouse VEGF-D/FIGF Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 15-25kDa.

Immobilized Mouse VEGFD(Catalog: RP01778) at 5 μg/mL (100 μL/well) can bind Human VEGFR-3/FLT-4 (Catalog: RP00123) with a linear range of 0.5-67.73 ng/mL.

All(2)|
货号: RP01778
促销价:   ¥780
货    期:现货产品
抗体定制服务咨询 |
商城订购

详细信息

种属
Mouse
表达宿主
HEK293 cells
描述
Recombinant Mouse VEGF-D/FIGF Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Phe98-Ser206) of Mouse VEGF-D/FIGF (Accession #NP_001295418.1) fused with a His tag at the C-terminus.
标签
C-6*His
纯度
PBS
内毒素
<0.1EU/μg
生物活性
Measured by its binding ability in a functional ELISA. Immobilized Mouse VEGFD(Catalog: RP01778) at 5 μg/mL (100 μL/well) can bind Human VEGFR-3/FLT-4 (Catalog: RP00123) with a linear range of 0.5-67.73 ng/mL.
制剂
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
储存
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月;
复溶之后,蛋白溶液在-20°C及以下可保存3个月,在2-8℃可保存1周。
复溶
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底,如果粉末浮起,开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL(请注意蛋白复溶浓度不能低于0.1 mg/mL),室温平衡5-10 min保证充分溶解,复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存,建议复溶时添加载体蛋白或者稳定剂(如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖),同时将复溶后的蛋白溶液按照需求进行分装,储存于-20°C至-80°C,随取随用,避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度,快速计算您需要添加溶液的体积吧!
=
÷

背景信息

Vascular endothelia growth factor D (VEGF-D), also known as c-fos-induced growth factor (FIGF), is a secreted glycoprotein of the VEGF/PDGF family. VEGFs regulate angiogenesis and lymphangiogenesis during development and tumor growth, and are characterized by eight conserved cysteine residues that form a cysteine-knot structure . VEGF-C and VEGF-D, which share 23% amino acid (aa) sequence identity, are uniquely expressed as preproproteins that contain long N- and C-terminal propeptide extensions around the VEGF homology domain (VHD) . Proteolytic processing of either 358 aa or 326 aa splice forms of mouse VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non-covalently linked 42 kDa homodimers of the 117 aa VHD . Mature mouse VEGF-D shares 94%, 99%, 93%, 91% and 89% aa identity with the VHD of human, rat, equine, canine and bovine VEGF-D, respectively. It is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin . Mouse and human VEGF-D are ligands for VEGF receptor 3 (VEGF-R3, also called Flt-4) that are active across species and show enhanced affinity when processed . Unlike human VEGF-D, which is also a ligand for VEGF-R2 (also called Flk-1 or KDR), mouse VEGF-D does not bind to VEGF-R2 . VEGF-R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium . While VEGF-C is the critical ligand for VEGF-R3 during embryonic lymphatic development, VEGF-D is most active in neonatal lymphatic maturation and bone growth . Both promote tumor lymphangiogenesis . Consonant with their activity on VEGF receptors, binding of VEGF-C and VEGF-D to neuropilins contributes to VEGF-R3 signaling in lymphangiogenesis, while binding to integrin alpha 9 beta 1 mediates endothelial cell adhesion and migration .

基因ID
Swiss Prot
别名
Vegfd; Figf;Vascular endothelial growth factor D; VEGF-D; c-Fos-induced growth factor; FIGF
>